Amarin (AMRN) Expected to Release Earnings on Wednesday

Key Points

• Amarin is expected to report Q3 2026 results before the market opens on Wednesday, October 28. Analysts forecast a loss of $0.0972 per share and revenue of approximately $43.76 million; the earnings call is scheduled for 8:00 a.m. ET.
• AMRN opened at $11.60, near its 52-week low of $11.25 and well below its 52-week high of $20.90. The company has a market capitalization of about $245 million and a negative P/E ratio of -11.72.
• Analyst sentiment is mixed, with ratings ranging from “strong buy” to “sell.” MarketBeat reports a consensus rating of Hold and a consensus price target of $13.00.

Amarin (NASDAQ:AMRN - Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect Amarin to announce earnings of ($0.0972) per share and revenue of $43.76 million for the quarter. Interested persons may review the information on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

Amarin Price Performance

Shares of AMRN opened at $11.60 on Friday. Amarin has a 1-year low of $11.25 and a 1-year high of $20.90. The stock has a market cap of $244.99 million, a PE ratio of -11.72 and a beta of 0.76. The firm has a fifty day moving average price of $13.19 and a 200 day moving average price of $14.17.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on AMRN shares. JPMorgan Chase & Co. assumed coverage on Amarin in a report on Friday, August 21st. They set an "underweight" rating and a $13.00 price objective on the stock. Wall Street Zen cut Amarin from a "buy" rating to a "hold" rating in a research report on Saturday, July 25th. Zacks Research raised Amarin from a "hold" rating to a "strong-buy" rating in a report on Monday, October 5th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Amarin in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $13.00.

Amarin Company Profile

Amarin Corporation plc NASDAQ: AMRN is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular disease. The company's primary product is icosapent ethyl, an omega-3 fatty acid formulation derived from eicosapentaenoic acid (EPA).

In the United States, icosapent ethyl is marketed as Vascepa and is approved as an adjunct to diet for certain patients with elevated triglyceride levels. It is also approved to reduce the risk of cardiovascular events, such as heart attack and stroke, in specified high-risk adult patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.